Aura Biosciences (AURA) News Today → Biden FINISHED On June 13th? (From Paradigm Press) (Ad) Free AURA Stock Alerts $7.30 +0.12 (+1.67%) (As of 12:33 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 10, 2024 | finance.yahoo.comAura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial OverviewMay 9, 2024 | investorplace.comAURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024May 9, 2024 | globenewswire.comAura Biosciences Reports First Quarter 2024 Financial Results and Business HighlightsMay 8, 2024 | finance.yahoo.comOne Aura Biosciences Insider Raised Stake By 232% In Previous YearMay 8, 2024 | globenewswire.comAura Biosciences to Participate in Upcoming Investor ConferencesApril 20, 2024 | msn.comFF16 Ultima Abilities And How To Unlock Them In The Rising TideApril 15, 2024 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Sees Significant Growth in Short InterestAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 2,450,000 shares, an increase of 9.4% from the March 15th total of 2,240,000 shares. Approximately 6.2% of the shares of the company are sold short. Based on an average daily volume of 179,700 shares, the days-to-cover ratio is presently 13.6 days.April 3, 2024 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Stake Raised by Regency Capital Management Inc. DERegency Capital Management Inc. DE boosted its stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 33.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 704,974 shares of the company's stock after buying an addMarch 29, 2024 | msn.com3 Best Stocks to Buy Now, 3/29/2024, According to Top AnalystsMarch 29, 2024 | markets.businessinsider.comAura Biosciences Inc: A Buy Rating on Strong Pipeline and Financial HealthMarch 28, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Molina Healthcare (MOH) and Aura Biosciences Inc (AURA)March 28, 2024 | finance.yahoo.comWe're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn RateMarch 27, 2024 | investorplace.comAURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023March 27, 2024 | benzinga.comRecap: Aura Biosciences Q4 EarningsMarch 27, 2024 | businesswire.comAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 13, 2024 | msn.comNational Assembly Counters Doctors Petition on SHIFMarch 13, 2024 | marketbeat.comDecheng Capital Management III Cayman LLC Buys 869,790 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)Decheng Capital Management III Cayman LLC boosted its stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 296.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,163,123 shares of the company's stocMarch 7, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Has $25.79 Million Position in Aura Biosciences, Inc. (NASDAQ:AURA)Adage Capital Partners GP L.L.C. raised its position in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 6.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,875,000 shares of the company's stock aFebruary 26, 2024 | businesswire.comAura Biosciences to Participate in Upcoming Investor ConferencesFebruary 25, 2024 | marketbeat.comAura Biosciences (AURA) Scheduled to Post Quarterly Earnings on MondayAura Biosciences (NASDAQ:AURA) will be releasing earnings on Monday, February 26, Yahoo Finance reports.February 23, 2024 | benzinga.comAura Biosciences Stock (NASDAQ:AURA), Short Interest ReportFebruary 16, 2024 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Sees Large Decrease in Short InterestAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,480,000 shares, a decrease of 5.7% from the January 15th total of 2,630,000 shares. Based on an average trading volume of 227,800 shares, the days-to-cover ratio is presently 10.9 days. Currently, 8.2% of the shares of the company are sold short.February 8, 2024 | marketbeat.comFY2024 EPS Estimates for Aura Biosciences, Inc. (NASDAQ:AURA) Lowered by AnalystAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Research analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for Aura Biosciences in a note issued to investors on Monday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earninFebruary 7, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Aura Biosciences, Inc.'s Q1 2024 Earnings (NASDAQ:AURA)Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for Aura Biosciences in a research report issued on Monday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings per share of ($0.45)January 24, 2024 | marketbeat.comInsider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) CFO Sells 6,609 Shares of StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) CFO Julie B. Feder sold 6,609 shares of the company's stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $7.64, for a total value of $50,492.76. Following the transaction, the chief financial officer now directly owns 62,991 shares in the company, valued at $481,251.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.January 7, 2024 | finance.yahoo.comOwning 48% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA),January 3, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)December 11, 2023 | finance.yahoo.comWall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a BetDecember 9, 2023 | benzinga.comAura Biosciences Stock (NASDAQ:AURA), Analyst Ratings, Price Targets, PredictionsDecember 7, 2023 | finance.yahoo.comAura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaNovember 23, 2023 | finance.yahoo.comWall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to TradeNovember 13, 2023 | markets.businessinsider.comCorrection: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common StockNovember 12, 2023 | finance.yahoo.comDavid Johnson Bought 232% More Shares In Aura BiosciencesNovember 11, 2023 | msn.comInsider Trading: Aura Biosciences Stock (NASDAQ:AURA) Bought by Insiders to the Tune of $16MNovember 10, 2023 | msn.comAura Biosciences director David Johnson buys common shares worth ~$1.44MNovember 10, 2023 | markets.businessinsider.comPortfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common StockNovember 8, 2023 | markets.businessinsider.comPromising Phase 2 Trial Results and Market Potential Bolster Aura Biosciences’ Buy RatingNovember 7, 2023 | msn.comWhy Aura Biosciences Stock Hit A New 52-Week Low TodayNovember 7, 2023 | markets.businessinsider.comAura Biosciences Prices Public Offering Of 11 Mln Shares Of At $9.00/shrNovember 6, 2023 | marketwatch.comAura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-SarNovember 6, 2023 | finance.yahoo.comAura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal MelanomaNovember 5, 2023 | morningstar.comAura Biosciences Inc AURANovember 1, 2023 | businesswire.comAura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with ...October 31, 2023 | finance.yahoo.comAura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023October 8, 2023 | finance.yahoo.comAura Biosciences Independent Chairman of the Board Acquires 30% More StockOctober 7, 2023 | uk.finance.yahoo.comAura Biosciences, Inc. (AURA) stock price, news, quote & history – Yahoo FinanceOctober 2, 2023 | barrons.comAura Biosciences Inc.October 2, 2023 | finance.yahoo.comAura Biosciences Strengthens and Expands Leadership Team with Key AppointmentsSeptember 13, 2023 | marketbeat.comLong Focus Capital Management LLC Purchases Shares of 171,377 Aura Biosciences, Inc. (NASDAQ:AURA)Long Focus Capital Management LLC purchased a new stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 171,377 shares of the company's stSeptember 8, 2023 | marketbeat.comMartingale Asset Management L P Takes Position in Aura Biosciences, Inc. (NASDAQ:AURA)Martingale Asset Management L P bought a new position in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 20,354 shares of the company's stock, valued at approximately $189,000. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Guard Against the Coming Financial Upheaval (Ad)America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late. You can stream it for free right here. AURA Media Mentions By Week AURA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AURA News Sentiment▼0.820.57▲Average Medical News Sentiment AURA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AURA Articles This Week▼91▲AURA Articles Average Week Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Black Diamond Therapeutics News Today Tenaya Therapeutics News Today Solid Biosciences News Today MeiraGTx News Today Jasper Therapeutics News Today Ocugen News Today Tourmaline Bio News Today Caribou Biosciences News Today TScan Therapeutics News Today SOPHiA GENETICS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AURA) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
